Background/Objectives: This study evaluates the impact of clinical, pathological, and treatment-related factors on breast cancer recurrence and overall survival following neoadjuvant chemotherapy and surgery.Patients and Method:A total of 298 patients treated at Diakoneo Diak Klinikum, Schwäbisch Hall, Germany (2010–2021) were analyzed. Key variables included hormone receptor status, molecular subtypes, tumor grade, treatment protocols, and metastatic disease at diagnosis.Results:Recurrence was strongly associated with metastatic disease (p< 0.001) but not with hormone receptor status or molecular subtypes. Platinum/taxane-based chemotherapy was linked to a lower recurrence risk (p= 0.05) compared to anthracycline-based regimens. Patients with recurrence had significantly lower overall survival (27.91% vs. 8.24%,p< 0.001). Logistic regression suggested a trend toward increased recurrence in ER-positive and PR-negative patients, though not statistically significant. These findings emphasize the importance of personalized treatment strategies and highlight the need for future studies incorporating genomic data and residual disease analysis to refine recurrence risk prediction and therapy selection.
背景/目的：本研究旨在评估临床、病理及治疗相关因素对乳腺癌患者在新辅助化疗及手术后复发与总生存期的影响。 患者与方法：对2010年至2021年间在德国施瓦本哈尔Diakoneo Diak Klinikum医院接受治疗的298例患者进行分析。关键变量包括激素受体状态、分子亚型、肿瘤分级、治疗方案及诊断时是否存在转移性疾病。 结果：复发与转移性疾病显著相关（p<0.001），但与激素受体状态或分子亚型无关。与基于蒽环类药物的方案相比，基于铂类/紫杉类药物的化疗方案复发风险更低（p=0.05）。复发患者的总生存率显著降低（27.91%对比8.24%，p<0.001）。逻辑回归分析显示，雌激素受体阳性且孕激素受体阴性患者的复发风险有升高趋势，但未达到统计学显著性。这些发现强调了制定个体化治疗策略的重要性，并指出未来研究需整合基因组数据及残留病灶分析，以优化复发风险预测和治疗选择。
肿瘤(癌症)患者之家